Polypeptide With Localisation/Targeting Motif TRIZ Cases

Peptide amphiphiles mimic heme oxygenase to neutralize toxic heme, resolving inflammatory responses while promoting tissue repair.

A polynucleotide encoding an HPV E6/E7 fusion protein stimulates robust CD8 and CD4 T cell responses.

Modified HSV-2 virus overcomes innate immune restrictions by utilizing a mutated ICP10 gene lacking protein kinase activity to enhance anti-tumor potency.

Lipocalin muteins replace scFv domains in chimeric antigen receptors to provide stable, monomeric antigen recognition on engineered T cells.

Engineered receptors bind mutated Fc domains on tumor antibodies, reducing off-target toxicity while maintaining anti-cancer efficacy.

Fusing porcine Fc fragments with target proteins resolves the contradiction between high productivity and low stability, improving isolation and storage.

Cellulose-binding domains enable high-purity protein isolation from plant bodies by adsorbing fusion proteins to cellulose and cleaving them with enterokinase.

Fusion proteins co-expressing CD70 CAR and IL-8 receptors improve glioblastoma targeting by resolving insufficient T cell localization.

Plant expression of the fusion protein ensures 1:1 stoichiometry and proper glycosylation, resolving solubility issues found in E. coli systems.

A PE-Pa01INT fusion protein integrates large donor DNA into target genome sites with high efficiency.

Modified clotting factor IX variants reduce neutralizing antibody formation and improve treatment durability for hemophilia B patients.

Administering a polypeptide antagonist targeting the Na/K ATPase/Src receptor complex extends red blood cell half-life without disrupting iron homeostasis.

Specific point mutations in costimulatory domains improve CAR-T persistence and antitumor efficacy while reducing exhaustion.

Merging antigen recognition, checkpoint blockade, and cytokine secretion into one construct overcomes immunosuppression while minimizing systemic toxicity.

Sortase chimeric antigen receptors mediate site-specific attachment of therapeutic agents to engineered T cell surfaces.

E163S substitution in light-responsive polypeptides accelerates channel closure kinetics, resolving slow response limits in optogenetic neural modulation.

Fusing MRSA antigens to CD40 ligand restores immune signaling in immunosuppressed patients, enabling effective vaccine response.

Disrupting endogenous antigen genes in engineered immune cells prevents fratricide killing while maintaining therapeutic efficacy.

Recombinant polypeptides with artificial ligands form switchable receptor complexes, enabling controlled signal transduction while preventing cytokine storms.

Segmented peptide structures balance permeation speed and retention reliability to overcome low skin permeability and circulation loss.

A diagnostic method using immunohistochemical staining to detect Numb expression levels for identifying cancer cells responsive to Notch inhibitory agents.

Engineered peptides inhibit p110beta activity to overcome chemoresistance in glioblastoma and melanoma treatments.

Chimeric receptors merge Fc-binding domains with ITAM signaling to overcome insufficient antibody-dependent cell-mediated cytotoxicity in cancer therapy.

Segmenting polypeptides into functional domains enables targeted enzyme delivery to tissues lacking specific receptors.

Fusion proteins direct antigens to endosomal compartments, enabling high-avidity T cell isolation despite poor tumor immunogenicity.

Variant CD80 fusion proteins block PD-L1 and CTLA-4 inhibitory signals to overcome immune checkpoint inhibition in cancer therapy.

Optimized CDR sequences in humanized antibodies target CLDN18.2 to resolve specificity conflicts with CLDN18.1 while improving therapeutic efficacy.

An intermediary FUT8 antibody reduces manufacturing costs by blocking enzyme activity without complex genetic engineering.

Autonomous adapter secretion by engineered immune cells reduces systemic toxicities and improves tumor tissue penetration.

Optimized amino acid sequences enhance cell membrane permeability, enabling efficient transfer of large polypeptides into the cytoplasm and nucleus.

Engineered transaminase polypeptides convert 3-hydroxyacetophenone to (S)-3-(1-aminoethyl)-phenol with high enantiomeric excess.

Molecular needle polypeptide aggregates transport norovirus immunogens into tissue cells, reducing required antigen dosage for effective vaccination.

A chimeric receptor merges an extracellular binding domain with a heterologous amino acid sequence to recruit a co-receptor for signal transmission.

Surface molecules bind T cell antigens to confer HIV resistance without CRISPR off-target cleavage.

Metagenomic sequencing identifies novel Type VI CRISPR/Cas enzymes from uncultivated microbes, expanding the diversity of available nucleic acid editing tools.

Non-peptidyl linkages arrange Fab and Fc domains into a tetrahedral structure, resolving planar geometry limits for simultaneous multi-target engagement.

CD70-specific TCR fusion proteins integrate antigen binding with signaling domains to improve T cell persistence while reducing fratricide.

C-terminal histidine tagging enables high-yield purification of TAT-HOXB4H fusion protein via nickel affinity chromatography.

Incorporating CD2 signaling domains into chimeric antigen receptors modulates T cell responses.

Disulfide bonds and albumin fusion stabilize IL-18, resolving low yield and rapid inactivation bottlenecks.

Truncated chimeric cytokine receptors modulate intracellular signaling to enhance T-cell proliferation and engraftment.

Segmented fusion protein with sterically occluded cleavage site eliminates ligand-independent background signals to improve signal-to-noise ratio.

Replacing IgG spacers with SIRP-alpha Ig-like C1 domains prevents off-target binding to Fc receptor-expressing myeloid cells, preserving CAR T cell longevity.

Anti-CRISPR polypeptides bind Cas9 complexes to inhibit cleavage, resolving the contradiction between editing capability and control.

Segmenting the RSV G protein into soluble ectodomains resolves production and solubility contradictions while maintaining immunogenicity.